Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | TPO | P07202 | 1/20 | 0.37 |
| ▸ | EPX | P11678 | 1/20 | 0.37 |
| ▸ | LPO | P22079 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133282 | 0.82 | LMNA (0.48) | MPOTPOEPXLPONOS3 | |
| SCHEMBL3333555 | 0.79 | NOS3 (0.42) | MPOTPOEPXLPONOS3 | |
| SCHEMBL10279192 | 0.77 | NOS3 (0.41) | MPOTPOEPXLPONOS3 | |
| SCHEMBL23634063 | 0.76 | NCF1 (0.47) | MPOTPOEPXLPONOS3 | |
| SCHEMBL30461582 | 0.75 | MPO (0.41) | MPOTPOEPXLPONOS3 | |
| SCHEMBL28663680 | 0.75 | MPO (0.41) | MPOTPOEPXLPONOS3 | |
| SCHEMBL610872 | 0.74 | ALOX5AP (0.38) | MPOTPOEPXLPOADRB2 | |
| SCHEMBL610871 | 0.74 | ALOX5AP (0.38) | MPOTPOEPXLPOADRB2 | |
| SCHEMBL18291228 | 0.73 | HIF1A (0.35) | MPOTPOEPXLPONOS3 | |
| SCHEMBL1920453 | 0.73 | RAB9A (0.54) | MCHR1MPOTPOEPXLPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | MCHR1 3616/4885MPO 1396/4885TPO 1383/4885 |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | MCHR1 3616/4885MPO 1396/4885TPO 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.